1. Amgen Inc. Erenumab (Aimovig™): US prescribing information. 2018.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf
. Accessed 8 June 2018.
2. European Medicines Agency. Summary of opinion (initial authorisation): Aimovig (erenumab). 2018.
http://www.ema.europa.eu
. Accessed 8 June 2018.
3. Amgen Inc. Amgen enters into neuroscience collaboration with Novartis for Alzheimer’s disease and migraine programs [media release]. 2015.
http://www.amgen.com
. Accessed 1 Sep 2015
4. Amgen Inc. Amgen announces expanded commercial collaboration with novartis for erenumab in migraine [media release]. 2017.
http://www.amgen.com
. Accessed 24 Apr 2017
5. Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356(1):223–31.